Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma

BACKGROUND: The prognosis of patients with metastatic malignant melanoma is very poor and partly due to resistance to conventional chemotherapies. The study’s objectives were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shumin, Fu, Qiang, Zhao, Lingdi, Fu, Xiaomin, Li, Tiepeng, Han, Lu, Qin, Peng, Ren, Yingkun, Huo, Mingke, Li, Zhimeng, Lu, Chaomin, Yuan, Long, Gao, Quanli, Wang, Zibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177116/
https://www.ncbi.nlm.nih.gov/pubmed/35348754
http://dx.doi.org/10.1093/oncolo/oyab068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177116/
https://www.ncbi.nlm.nih.gov/pubmed/35348754
http://dx.doi.org/10.1093/oncolo/oyab068

Ejemplares similares